Extracoporeal clearance and extracorporeal clearance fraction: Pharmacokinetic bases and drug dosing in continuous extracorporeal treatments;Concepto de aclaramiento extracorpóreo y fracción de aclaramiento extracorpóreo: Conceptos farmacocinéticos y ajuste de dosis en técnicas continuas

Nefrologia

Volumn 27, Issue SUPPL.3, 2007, Pages 247-255

  Maynar, J ^a  

^a HOSPITAL TXAGORRITXU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876097098     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. a ed. Bogotá/Buenos Aires: Panamericana 1991.
2. Kroh UF: Drug administration in critically ill patients with acute renal failure. New Horizons 3: 748-759, 1995.
3. Schetz M Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 21: 612-620, 1995.
4. Golper TA, Marx MA Drug dosing adjustments during continuous renal replacement therapies. Kidney International 53 (S66): 165-168, 1998.
5. Joos B Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 11: 1582-1585, 1996.
6. Bressolle F y cols.: Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 26 (6): 45-471, 1994.
7. Golper TA Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. International J Artif Organs 8 (6): 307-312, 1985.
8. Golper TAy cols.: Drug removal during continuous renal replacement therapies. Dyalisis y Transplantation 22 (4): 185-212, 1993.
9. Vincent HH Drug clearance by continuous haemofiltration. Blood Purif 11: 99-107, 1993.
10. Bickley SK Drug dosing during continuous arteriovenous hemofiltration. Clinical Pharmacy 7: 198-206, 1988.
11. Sanz C Corrección de dosis de fármacos en pacientes en hemofiltración. Clínica Española 198: 70-76, 1998.
12. Wolter K Teicoplanin pharmacokinetics and dosage recomendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis. Clinical nephrology 42: 389-397, 1994.
13. Maynar J, López J, Sánchez Izquierdo JA Administración de Fármacos y de Nutrición Artificial en las TCRR. En: Maynar J, Sánchez-Izquierdo JA. Fallo Renal Agudo y Técnicas de Depuración Extracorpórea. Barcelona, Editorial EDIKA MED 177-191, 2001.
14. Malone RS, Fish DN, Abraham E, Teitelbaum I Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 45: 3148-3155, 2001.
15. Isla A, Gascon AR, Maynar J, Arzuaga A, Toral D, Pedraz JL Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clinical Therapeutics 27 (5): 599-608, 2005.
16. Traunmuller F, Schenk P, Mittermeyer C, Thalhammer-Scherrer R, Ratheiser K, Thalhammer F Clearance of ceftazidime during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother 49: 129-134, 2002.
17. Isla A, Arzuaga A, Maynar J, Gascon AR, Solinis MA, Corral E, Pedraz JL Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC. Journal of Pharmaceutical & Biomedical Analysis 39 (5): 996-1005, 2005.
18. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 47: 421-429, 2001.
19. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 36: 1114-1119, 1996.
20. Matzke GR, Frye RF, Joy MS, Palevsky PM Determinants of ceftriaxone clearance by continuous veno-venous hemofiltration and hemodialysis. Pharmacotherapy 20 (6): 635-43, 2000.
21. Wallis SC, Mullany DV, Lipman J, Rickard CM, Daley PJ Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 27: 665-672, 2001.
22. Malone RS, Fish DN, Abraham E, Teitelbaum I Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 45: 2949-2954, 2001.
23. Bellmann R, Egger P, Gritsch W, Bellmann-Weiler R, Joannidis M, Dunzendorfer S, Wiedermann ChJ Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous veno-venous haemofiltration: influence of concomitant liver cirrhosis. Acta Med Austriaca 29 (3): 112-6, 2002.
24. Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, Iseki K Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 29: 1844-1848, 2003.
25. Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit Care Med 26 (1): 184-7, 1998.
26. Kishino S, Takekuma Y, Sugawara M, Shimamura T, Furukawa H, Todo S, Miyazaki K Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. J Chromatogr 780: 289-294, 2002.
27. Fish DN, Teitelbaum I, Abraham E Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 49: 2421-2428, 2005.
28. Tegeder I, Bremer F, Oelkers R, Schobel H, Schuttler J, Brune K, Geisslinger G Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous veno-venous hemofiltration. Antimicrob Agents Chemother 41 (12): 2640-5, 1997.
29. Hansen E, Bucher M, Jacob W, Lemberger P, Kees F Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intensive Care Med 27: 371-375.
30. Meyer B, Kornek GV, Nikfardjam M, Karth GD, Heinz G, Locker GJ, Jaeger W, Thalhammer F Multiple-dose pharmacokinetics of linezolid during continuous veno-venous haemofiltration. J Antimicrob Chemother 56: 172-179, 2005.
31. Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Parenti E, Picetti E, Sagripanti S, Manini P, Andreoli R, Cabassi A Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous veno-venous hemofiltration in patients with acute renal failure. Crit Care Med 32: 2437-2442, 2004.
32. Kuti JL, Nicolau DP Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy 51: 211-216, 2005.
33. Isla A, Maynar J, Sánchez-Izquierdo JA, Gascon AR, Arzuaga A, Corral E, Pedraz JL Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 45 (11): 1294-304, 2005.
34. Tegeder I, Neumann F, Bremer F y cols.: Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous veno-venous hemofiltration. Clin Pharmacol Ther 65: 50-57, 1999.
35. Lamp KC, Freeman CD, Klutman NE, Lacy MK: Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36: 353-373, 1999.
36. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ Elimination of the piperacillin/tazobactam combination during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 48: 881-885, 2001.
37. Van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 23: 873-877, 1997.
38. Arzuaga A, Maynar J, Gascón AR, Isla A, Corral E, Fonseca F, Sánchez-Izquierdo JA, Rello J, Canut A, Pedraz JL Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous veno-venous hemofiltration. J Clin Pharmacol 45 (2): 168-76, 2005.
39. Thalhammer F, Rosenkranz AR, Burgmann H, Graninger W, Hollenstein U, Schenk P, Thalhammer-Scherrer R, Traindl O, Horl WH, Breyer S Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. Wien Klin Wochenschr 109: 362-365, 1997.
40. Yagasaki K, Gando S, Matsuda N y cols.: Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Intensive Care Med 29: 2094-2095, 2003.
41. DelDot ME, Lipman J, Tett SE Vancomycin pharmacokinetics in critically ill patients receiving continuous veno-venous haemodiafiltration. Br J Clin Pharmacol 58: 259-268, 2004.
42. Boereboom F, Ververs F, Blankestijn P, Savelkoul T, Van Dijk A Vancomycin clearance during continuous veno-venous haemofiltration in critically ill patients. Intensive Care Med 25: 1100-1104, 1999.